ATTR amyloidosis

March 27, 2026 Five Things to Know about TRITON-CM & How Community Insight is Shaping the Future of ATTR- ... TRITON-CM, Alnylam's Phase 3 clinical trial evaluating nucresiran, a third-generation investigational RNAi therapeutic for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), represents one of the largest global studies ever conducted in this disease. Read More ›

September 6, 2023 First Consensus Recommendations for Holistic Care of People Living With Hereditary ATTR Am ... The Amyloidosis Alliance has published the first-ever consensus recommendations for patient- and family-centred holistic care in ATTRv. Read More ›

September 6, 2021 Co-Creating with Patients, for Patients: Addressing Unmet Needs in Conversations about AT ... Collaborating with patient organizations and patients is an essential part of our efforts to support people living with a complex rare disease like... Read More ›

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site

FOLLOW US